Edwards Lifesciences — Apr 23, 2025 release

Recent Highlights • Q1 sales grew 6.2% to $1.41 billion, or 7.9% adjusted 1 • Q1 TAVR sales grew 3.8%; constant currency 1 sales grew 5.4%, better than expected • Q1 TMTT sales grew 58% to $115 million with meaningful contribution to Edwards' growth • Q1 EPS of $0.62 2 ; adjusted 1 EPS of $0.64 • SAPIEN M3 CE Mark approval uniquely positions Edwards with a comprehensive TMTT portfolio • NCD finalized for transcatheter tricuspid valve replacement, expanding patient access to EVOQUE • Multiple TAVR studies presented at ACC confirm the need for urgent patient referral to Heart Team • Data from Heart Valve Society meeting confirm long-term durability of Edwards’ RESILIA tissue 2025 Outlook • Raising TMTT sales guidance range to $530 million to $550 million • Reiterating TAVR and Surgical sales growth guidance • Reiterating 8-10% Edwards sales growth guidance; increasing sales guidance to $5.7 to $6.1 billion • Reaffirming adjusted EPS of $2.40 to $2.50, including estimated JenaValve dilution and tariff impact “The many milestones achieved this quarter are the result of our structural heart-focused strategy and our decades of unwavering dedication to driving breakthrough innovation in pioneering and leading categories. Collectively, these milestones mark the significant progress we have made to unlock this large and growing opportunity to transform care for millions of structural heart patients around the world,” said Bernard Zovighian, CEO. “We are pleased with our strong start to the year and have confidence in our 2025 outlook. Looking to the future, we will build on the many impactful catalysts for our company, which position us for distinguished growth in the years ahead.” Transcatheter Aortic Valve Replacement (TAVR) In the first quarter, the company reported TAVR sales of $1.05 billion, wh ich grew 3.8% vers us the prior year, 5.4% on a constant currency basis, or 6.5% further adjusted for one less billing day. Constant currency growth was comparable in the United States ("U.S.") and Outside of the United States ("OUS"). Edwards' strong competitive position and pricing remained stable globally, with some regional variabili